BioSpace News Archive

Genetown

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Neumora Therapeutics, Inc. today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Monday, January 8, 2024 at 11:15 a.m. PT (2:15 p.m. ET).

January 2, 2024
·
1 min read
ExCellThera to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference and to Participate in Upcoming Investor Conferences

ExCellThera Inc. announced today that its senior leaders will be holding investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA, and will be participating in the following investor conferences in January:

January 2, 2024
·
3 min read
Genetown

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

Kymera Therapeutics, Inc. today announced the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET.

January 2, 2024
·
1 min read
Biotech Bay

ASLAN Pharmaceuticals Announces Participation in January Investor Conferences - January 2, 2024

ASLAN Pharmaceuticals today announced its participation in upcoming conferences for January 2024.

January 2, 2024
·
1 min read
Bio NC

Labcorp to Speak at the 42nd Annual J.P. Morgan Healthcare Conference

Labcorp announced today that members of the executive management team will participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9 at 4:30 p.m. (PT).

January 2, 2024
·
1 min read
Genetown

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01.

January 2, 2024
·
5 min read
Business

SimBioSys and Mayo Clinic Enter Strategic Collaboration to Advance AI-powered Digital Precision Medicine Platform for Cancer Patients

SimBioSys announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.

January 2, 2024
·
3 min read
Pharm Country

European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors

European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1 -Positive Non-Small Cell Lung Cancer and NTRK -Positive Solid Tumors.

January 2, 2024
·
18 min read
BioCapital

Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

Altimmune, Inc. today announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease 1 will be presented at the NASH-TAG Conference, which will be held in Park City, UT on January 4-6, 2024.

January 2, 2024
·
1 min read
Deals

XOMA Announces Stock Repurchase Program of up to $50 Million

XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized XOMA’s first stock repurchase program, which permits the Company to purchase up to $50 million of XOMA’s common stock through January 2027.

January 2, 2024
·
4 min read